Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Lessened by Kendall Capital Management

Kendall Capital Management trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,212 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Kendall Capital Management’s holdings in Regeneron Pharmaceuticals were worth $1,403,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC grew its holdings in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 686 shares during the period. IFP Advisors Inc boosted its position in shares of Regeneron Pharmaceuticals by 17.2% during the 4th quarter. IFP Advisors Inc now owns 368 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 54 shares in the last quarter. SVB Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $707,000. Fisher Asset Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 16.5% in the 4th quarter. Fisher Asset Management LLC now owns 5,890 shares of the biopharmaceutical company’s stock worth $4,197,000 after purchasing an additional 833 shares during the last quarter. Finally, US Bancorp DE raised its holdings in shares of Regeneron Pharmaceuticals by 21.6% in the 4th quarter. US Bancorp DE now owns 6,066 shares of the biopharmaceutical company’s stock worth $4,321,000 after purchasing an additional 1,078 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research reports. Citigroup reduced their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating for the company in a report on Monday, June 2nd. Robert W. Baird reduced their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research note on Friday, April 25th. JPMorgan Chase & Co. decreased their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a report on Monday, June 9th. The Goldman Sachs Group reduced their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Finally, Bank of America decreased their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $822.58.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $521.00 on Monday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The stock’s 50-day moving average is $554.18 and its two-hundred day moving average is $631.19. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The firm has a market cap of $56.25 billion, a P/E ratio of 13.26, a PEG ratio of 1.91 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company’s quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $9.55 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.68%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.